Pulmotect, Inc.
  • Home
  • About Us
    • Our Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Approach
    • Overview
    • Our Science
    • Our Pipeline
    • Published Journal Articles
  • News
  • Contact Us

Pulmotect Initiates Landmark Phase 2 Clinical Trial in Immunosuppressed Cancer Patients

Posted on July 10, 2025 by admin
Posted in Press Releases

Post navigation

Pulmotect Raises $5.9M Series C Round Led by Fannin Partners
Pulmotect Inc

3900 Essex Ln, Suite 575
Houston, TX 77027
Contact Us

© 2025
Pulmotect, Inc.